These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

659 related items for PubMed ID: 30027278

  • 1. Timing of Onset of Adverse Cutaneous Reactions Associated With Programmed Cell Death Protein 1 Inhibitor Therapy.
    Wang LL, Patel G, Chiesa-Fuxench ZC, McGettigan S, Schuchter L, Mitchell TC, Ming ME, Chu EY.
    JAMA Dermatol; 2018 Sep 01; 154(9):1057-1061. PubMed ID: 30027278
    [Abstract] [Full Text] [Related]

  • 2. Disproportionality analysis of bullous pemphigoid adverse events with PD-1 inhibitors in the FDA adverse event reporting system.
    Aggarwal P.
    Expert Opin Drug Saf; 2019 Jul 01; 18(7):623-633. PubMed ID: 31088310
    [Abstract] [Full Text] [Related]

  • 3. Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management.
    Coleman E, Ko C, Dai F, Tomayko MM, Kluger H, Leventhal JS.
    J Am Acad Dermatol; 2019 Apr 01; 80(4):990-997. PubMed ID: 30399387
    [Abstract] [Full Text] [Related]

  • 4. Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy.
    Siegel J, Totonchy M, Damsky W, Berk-Krauss J, Castiglione F, Sznol M, Petrylak DP, Fischbach N, Goldberg SB, Decker RH, Stamatouli AM, Hafez N, Glusac EJ, Tomayko MM, Leventhal JS.
    J Am Acad Dermatol; 2018 Dec 01; 79(6):1081-1088. PubMed ID: 30025829
    [Abstract] [Full Text] [Related]

  • 5. Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: A retrospective case-control study.
    Min Lee CK, Li S, Tran DC, Zhu GA, Kim J, Kwong BY, Chang ALS.
    J Am Acad Dermatol; 2018 Dec 01; 79(6):1047-1052. PubMed ID: 29857011
    [Abstract] [Full Text] [Related]

  • 6. Lupus-like cutaneous reaction following pembrolizumab: An immune-related adverse event associated with anti-PD-1 therapy.
    Shao K, McGettigan S, Elenitsas R, Chu EY.
    J Cutan Pathol; 2018 Jan 01; 45(1):74-77. PubMed ID: 29028121
    [Abstract] [Full Text] [Related]

  • 7. Cutaneous adverse reactions to anti-PD-1 treatment-A systematic review.
    Simonsen AB, Kaae J, Ellebaek E, Svane IM, Zachariae C.
    J Am Acad Dermatol; 2020 Nov 01; 83(5):1415-1424. PubMed ID: 32320766
    [Abstract] [Full Text] [Related]

  • 8. Investigation of clinical factors associated with longer overall survival in advanced melanoma patients treated with sequential ipilimumab.
    Muto Y, Kitano S, Tsutsumida A, Namikawa K, Takahashi A, Nakamura Y, Yamanaka T, Yamamoto N, Yamazaki N.
    J Dermatol; 2019 Jun 01; 46(6):498-506. PubMed ID: 30945333
    [Abstract] [Full Text] [Related]

  • 9. Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy.
    Marano AL, Clarke JM, Morse MA, Shah A, Barrow W, Selim MA, Hall RP, Cardones AR.
    Br J Dermatol; 2019 Sep 01; 181(3):580-583. PubMed ID: 30244487
    [Abstract] [Full Text] [Related]

  • 10. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.
    Brunot A, Grob JJ, Jeudy G, Grange F, Guillot B, Kramkimel N, Mortier L, Le Corre Y, Aubin FF, Mansard S, Lebbé C, Blom A, Montaudie H, Giacchero D, Prey S, Legoupil D, Guyot A, Amini-Adle M, Granel-Brocard F, Meyer N, Dinulescu M, Edeline J, Campillo-Gimenez B, Lesimple T.
    JAMA Dermatol; 2020 Sep 01; 156(9):982-986. PubMed ID: 32667663
    [Abstract] [Full Text] [Related]

  • 11. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort.
    Hwang SJ, Carlos G, Wakade D, Byth K, Kong BY, Chou S, Carlino MS, Kefford R, Fernandez-Penas P.
    J Am Acad Dermatol; 2016 Mar 01; 74(3):455-61.e1. PubMed ID: 26793994
    [Abstract] [Full Text] [Related]

  • 12. Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis.
    Chorti E, Kanaki T, Zimmer L, Hadaschik E, Ugurel S, Gratsias E, Roesch A, Bonella F, Wessendorf TE, Wälscher J, Theegarten D, Schadendorf D, Livingstone E.
    Eur J Cancer; 2020 May 01; 131():18-26. PubMed ID: 32248071
    [Abstract] [Full Text] [Related]

  • 13. Characterization and Prognostic Significance of Cutaneous Adverse Events to Anti-Programmed Cell Death-1 Therapy.
    Lee YJ, Kim HT, Won CH, Chang SE, Lee MW, Choi JH, Lee WJ.
    J Korean Med Sci; 2019 Jul 08; 34(26):e186. PubMed ID: 31269545
    [Abstract] [Full Text] [Related]

  • 14. Late presentation of generalised bullous pemphigoid-like reaction in a patient treated with pembrolizumab for metastatic melanoma.
    Parakh S, Nguyen R, Opie JM, Andrews MC.
    Australas J Dermatol; 2017 Aug 08; 58(3):e109-e112. PubMed ID: 27170423
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Association of good oncological response to therapy with the development of rheumatic immune-related adverse events following PD-1 inhibitor therapy.
    Liew DFL, Leung JLY, Liu B, Cebon J, Frauman AG, Buchanan RRC.
    Int J Rheum Dis; 2019 Feb 08; 22(2):297-302. PubMed ID: 30549256
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Granulomatous and lichenoid dermatitis after IgG4 anti-PD-1 monoclonal antibody therapy for advanced cancer.
    Diaz-Perez JA, Beveridge MG, Victor TA, Cibull TL.
    J Cutan Pathol; 2018 Jun 08; 45(6):434-438. PubMed ID: 29468713
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Eruptive keratoacanthomas arising in the setting of lichenoid toxicity after programmed cell death 1 inhibition with nivolumab.
    Feldstein SI, Patel F, Larsen L, Kim E, Hwang S, Fung MA.
    J Eur Acad Dermatol Venereol; 2018 Feb 08; 32(2):e58-e59. PubMed ID: 28776778
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.